Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 8/20 | 0.63 |
| ▸ | CCR5 | P51681 | 4/20 | 0.45 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6041692 | 1.00 | TACR1 (0.63) | TACR1CCR5APOBEC3ARECQLAPOBEC3G | |
| SCHEMBL1339508 | 0.84 | TACR1 (0.59) | TACR1SIGMAR1GRIN1GRIN2BKDM4E | |
| SCHEMBL31193852 | 0.84 | TACR1 (0.59) | TACR1SIGMAR1GRIN1GRIN2BKDM4E | |
| Hydrochloric Acid SCHEMBL19946931 | 0.83 | TACR1 (0.60) | TACR1SIGMAR1GRIN1GRIN2BKDM4E | |
| SCHEMBL1618266 | 0.82 | TACR1 (0.61) | TACR1SIGMAR1GRIN1GRIN2BACHE | |
| SCHEMBL6041583 | 0.82 | TACR1 (0.61) | TACR1SIGMAR1GRIN1GRIN2BACHE | |
| SCHEMBL6042019 | 0.82 | TACR1 (0.57) | TACR1SIGMAR1GRIN1GRIN2BKMT2A | |
| SCHEMBL6042023 | 0.82 | TACR1 (0.57) | TACR1SIGMAR1GRIN1GRIN2BKMT2A | |
| SCHEMBL28164936 | 0.81 | TACR1 (0.59) | TACR1SIGMAR1GRIN1GRIN2BACHE | |
| SCHEMBL5870998 | 0.81 | TACR1 (0.59) | TACR1APOBEC3ARECQLAPOBEC3GSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060079533-A1 | Methods of treating alzheimer's disease | NIEMAN JAMES A | 2006-04-13 | — | — | US | disclosed |
| EP-0863875-B1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | HOFFMANN LA ROCHE (CH) | 2003-06-04 | — | — | EP | disclosed |
| US-6150526-A | Piperidine derivative having renin inhibiting activity | HOFFMANN-LA ROCHE INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6051712-A | PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS | HOFFMANN-LA ROCHE INC. (US) | 2000-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079533-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, PSEN2 | TACR1 508/4885CCR5 2844/4885APOBEC3A 2179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.